BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1469935)

  • 1. Alterations in thyroid and hepatic function tests associated with preparations of sustained-release niacin.
    Drinka PJ
    Mayo Clin Proc; 1992 Dec; 67(12):1206. PubMed ID: 1469935
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatotoxicity associated with sustained-release niacin.
    Dalton TA; Berry RS
    Am J Med; 1992 Jul; 93(1):102-4. PubMed ID: 1626557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis caused by low-dose sustained-release niacin.
    Schwenk TL; Fisher M
    J Am Board Fam Pract; 1994; 7(3):242-4. PubMed ID: 8059629
    [No Abstract]   [Full Text] [Related]  

  • 4. Transient focal hepatic defects related to sustained-release niacin.
    Lawrence SP
    J Clin Gastroenterol; 1993 Apr; 16(3):234-6. PubMed ID: 8505497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fulminant hepatic failure following low-dose sustained-release niacin therapy in hospital.
    Fischer DJ; Knight LL; Vestal RE
    West J Med; 1991 Oct; 155(4):410-2. PubMed ID: 1771885
    [No Abstract]   [Full Text] [Related]  

  • 6. Acute hepatic failure associated with the use of low-dose sustained-release niacin.
    Hodis HN
    JAMA; 1990 Jul; 264(2):181. PubMed ID: 2355439
    [No Abstract]   [Full Text] [Related]  

  • 7. Rechallenge with crystalline niacin after drug-induced hepatitis from sustained-release niacin.
    Henkin Y; Johnson KC; Segrest JP
    JAMA; 1990 Jul; 264(2):241-3. PubMed ID: 2355446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic toxicity of unmodified and time-release preparations of niacin.
    Rader JI; Calvert RJ; Hathcock JN
    Am J Med; 1992 Jan; 92(1):77-81. PubMed ID: 1731514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical inquiries. Should liver enzymes be checked in a patient taking niacin?
    Rizakallah GS; Mertens MK; Brown ML; Sanner L
    J Fam Pract; 2005 Mar; 54(3):265-8. PubMed ID: 15755381
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety and side effects of sustained-release niacin.
    Lavie CJ; Milani RV
    JAMA; 1994 Aug; 272(7):513-4; author reply 514-5. PubMed ID: 8046796
    [No Abstract]   [Full Text] [Related]  

  • 11. Fulminant hepatic failure after ingestion of sustained-release nicotinic acid.
    Mullin GE; Greenson JK; Mitchell MC
    Ann Intern Med; 1989 Aug; 111(3):253-5. PubMed ID: 2665592
    [No Abstract]   [Full Text] [Related]  

  • 12. Comment: adverse-effect profile of sustained-release niacin.
    Jungnickel PW; Maloley PA
    DICP; 1991 Sep; 25(9):1014-5. PubMed ID: 1949965
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety of extended-release niacin/laropiprant in patients with dyslipidemia.
    McKenney J; Bays H; Koren M; Ballantyne CM; Paolini JF; Mitchel Y; Betteridge A; Kuznetsova O; Sapre A; Sisk CM; Maccubbin D
    J Clin Lipidol; 2010; 4(2):105-112.e1. PubMed ID: 21122637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and side effects of sustained-release niacin.
    Keenan JM; Ripsin CM; Huang Z; McCaffrey DJ
    JAMA; 1994 Aug; 272(7):513; author reply 514-5. PubMed ID: 8046795
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety and side effects of sustained-release niacin.
    Shields M; Beckmann SL
    JAMA; 1994 Aug; 272(7):514; author reply 514-5. PubMed ID: 8046797
    [No Abstract]   [Full Text] [Related]  

  • 16. Adverse effects of sustained-release niacin.
    Knapp TR; Middleton RK
    DICP; 1991 Mar; 25(3):253-4. PubMed ID: 2028632
    [No Abstract]   [Full Text] [Related]  

  • 17. Niacin and hepatic failure.
    Knopp RH
    Ann Intern Med; 1989 Nov; 111(9):769. PubMed ID: 2802441
    [No Abstract]   [Full Text] [Related]  

  • 18. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients.
    McKenney JM; Proctor JD; Harris S; Chinchili VM
    JAMA; 1994 Mar; 271(9):672-7. PubMed ID: 8309029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study.
    Rubenfire M;
    Am J Cardiol; 2004 Aug; 94(3):306-11. PubMed ID: 15276093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacoepidemiology of niacin.
    Jungnickel PW; Maloley PA
    Ann Intern Med; 1995 Mar; 122(5):392-3. PubMed ID: 7847654
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.